OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Andreas Jeromin

1 Projects | 1 Researchers | $1,910,202 Invested

2023

ALZPath, Inc.

Andreas Jeromin, PhD

Validation of a novel, accessible, scalable, and affordable blood-based p-tau 217 assay for clinical use

  • Funding Amount: $1,910,202
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Neuronal Degeneration
  • Status: Closed